Apellis Pharmaceuticals Inc (FRA:1JK)
€ 36.59 -0.37 (-1%) Market Cap: 4.53 Bil Enterprise Value: 4.33 Bil PE Ratio: 0 PB Ratio: 18.22 GF Score: 49/100

Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 01:15PM GMT
Release Date Price: €38.2 (-4.02%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everyone, to the 40th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Priyanka Grover, Malcolm Kuno and Caleb Smith from the team. Our next presenting company is Apellis and presenting on behalf of the company, we have CEO Cedric Francois. I want to remind the attendees of this session to use the Ask the question feature in the portal, and I would be happy to ask the question on your behalf. With that, Cedric, take it away.

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

Thank you so much, Anupam, and thank you for inviting us again to this conference. I wished it was in person, but hopefully next year, that will be the case. So starting with our first slide, Slide #2 are forward-looking statements. And going to Slide #3. First, taking a quick look back at year 2021, which was an extraordinary year for us. We continued to position ourselves to be the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot